| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Exifone does not have a single well-characterized molecular target. As a benzophenone derivative with multiple hydroxyl groups, it may interact with various proteins and enzymes through hydrogen bonding and metal chelation. Its mechanism of action would depend on the specific biological assay being studied.
|
|---|---|
| ln Vitro |
In biochemical assays, exifone has been characterized as a bioactive compound. Its activity would be assessed in cell-free systems depending on the specific target or pathway being investigated. The compound's multiple hydroxyl groups suggest potential antioxidant or enzyme inhibitory activities.
|
| ln Vivo |
Cells are treated with exifone to assess its biological effects. Endpoints depend on the specific study but may include assessment of cell viability, oxidative stress markers, enzyme activity, or signaling pathway modulation. Detailed cellular activity data are described in the primary literature.
|
| Enzyme Assay |
The in vitro assay for exifone would depend on the specific biological activity being studied. Standard protocols for enzyme inhibition, antioxidant activity, or receptor binding assays would be employed. These typically involve incubating the compound with the target protein or assay system, followed by detection using appropriate methods.
|
| Cell Assay |
Cells are cultured and treated with exifone at concentrations ranging from 1-100 µM. Endpoints include assessment of cell viability by MTT, measurement of oxidative stress markers, or analysis of specific signaling pathways. Cytotoxicity is monitored to determine the compound's safety profile.
|
| Animal Protocol |
In vivo studies for exifone would be conducted in appropriate animal models depending on the biological question being addressed. The compound would be administered via routes such as oral gavage, intraperitoneal injection, or intravenous injection. Endpoints would depend on the specific study objectives.
|
| ADME/Pharmacokinetics |
Exifone (C₁₃H₁₀O₇, MW 278.22, CAS 52479-85-3) is a small molecule compound. It has a melting point of 245°C and a density of 1.759 g/cm³. The compound is typically stored as a powder at -20°C for up to 3 years. It may dissolve in DMSO.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology data for exifone are limited. The compound is for research use only and is not approved for clinical use. Standard safety precautions should be followed when handling the compound.
|
| Additional Infomation |
(2,3,4-Trihydroxyphenyl)-(3,4,5-Trihydroxyphenyl) methyl ketone is a member of the benzophenone class of compounds.
Exifone (also known as NSC-680919 and NSC 680919) is a benzophenone-class bioactive compound. It is a research tool for studying various biological activities. The compound is intended for laboratory use only and is not approved for human therapeutic use. |
| Molecular Formula |
C13H10O7
|
|---|---|
| Molecular Weight |
278.22
|
| Exact Mass |
278.043
|
| CAS # |
52479-85-3
|
| PubChem CID |
40399
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.759 g/cm3
|
| Boiling Point |
674.6ºC at 760 mmHg
|
| Melting Point |
245°C
|
| Flash Point |
375.8ºC
|
| Index of Refraction |
1.795
|
| LogP |
1.151
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
349
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C(=C1C(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O
|
| InChi Key |
XEDWWPGWIXPVRQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H10O7/c14-7-2-1-6(11(18)13(7)20)10(17)5-3-8(15)12(19)9(16)4-5/h1-4,14-16,18-20H
|
| Chemical Name |
(2,3,4-trihydroxyphenyl)-(3,4,5-trihydroxyphenyl)methanone
|
| Synonyms |
Exifone NSC-680919 NSC680919NSC 680919
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5943 mL | 17.9714 mL | 35.9428 mL | |
| 5 mM | 0.7189 mL | 3.5943 mL | 7.1886 mL | |
| 10 mM | 0.3594 mL | 1.7971 mL | 3.5943 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02464696 | RECRUITING | Drug: Methylprednisolone Procedure: Oxygen Therapy Device: Positive Air Pressure Device |
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm |
M.D. Anderson Cancer Center | 2015-10-06 | Not Applicable |
| NCT04479267 | RECRUITING | Drug: Prednisone Drug: Prednisolone Drug: Methylprednisolone |
Diffuse Large B-Cell Lymphoma Double Expressor Lymphoma High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements High-grade B-cell Lymphoma |
Barbara Ann Karmanos Cancer Institute | 2020-08-21 | Phase 2 |
| NCT01624805 | RECRUITING | Biological: Anti-Thymocyte Globulin Drug: Cyclosporine Biological: Filgrastim |
Aplastic Anemia Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome de Novo Myelodysplastic Syndrome |
M.D. Anderson Cancer Center | 2012-06-25 | Phase 2 |
| NCT04151082 | RECRUITING | Drug: Methylprednisolone Drug: Prednisone Other: Quality-of-Life Assessment Other: Questionnaire Administration |
Cranial Nerve Disorder Head and Neck Carcinoma Oropharyngeal Carcinoma |
M.D. Anderson Cancer Center | 2019-10-31 | Phase 1 Phase 2 |
| NCT01331018 | TERMINATED | Procedure: Bone Marrow Aspiration Biological: Filgrastim Biological: Genetically Engineered Hematopoietic Stem Progenitor Cells |
Fanconi Anemia | Fred Hutchinson Cancer Center | 2012-02-22 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
